<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35240914</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges.</ArticleTitle>
        <Pagination>
          <StartPage>2035117</StartPage>
          <MedlinePgn>2035117</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2035117</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2035117</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune diseases are caused when immune cells act against self-protein. This biological self-non-self-discrimination phenomenon is controlled by a distinct group of lymphocytes known as regulatory T cells (Tregs), which are key inflammatory response regulators and play a pivotal role in immune tolerance and homeostasis. Treg-mediated robust immunosuppression provides self-tolerance and protection against autoimmune diseases. However, once this system fails to operate or poorly operate, it leads to an extreme situation where immune system reacts against self-antigens and destroys host organs, thus causing autoimmune diseases. Tregs can target both innate and adaptive immunity via modulating multiple immune cells such as neutrophils, monocytes, antigen-presenting cells, B cells, and T cells. This review highlights the Treg-mediated immunosuppression, role of several markers and their interplay during Treg development and differentiation, and advances in therapeutic aspects of Treg cells to reduce severity of autoimmunity-related conditions along with emphasizing limitations and challenges of their usages.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Goswami</LastName>
            <ForeName>Tapas Kumar</ForeName>
            <Initials>TK</Initials>
            <Identifier Source="ORCID">0000-0002-0518-2179</Identifier>
            <AffiliationInfo>
              <Affiliation>Immunology Section, ICAR-Indian Veterinary Research Institute, Bareilly, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Mithilesh</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-2316-9303</Identifier>
            <AffiliationInfo>
              <Affiliation>Immunology Section, ICAR-Indian Veterinary Research Institute, Bareilly, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dhawan</LastName>
            <ForeName>Manish</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-7783-7138</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, Punjab Agricultural University, Ludhiana, India.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Trafford Group of Colleges, Manchester, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mitra</LastName>
            <ForeName>Saikat</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Emran</LastName>
            <ForeName>Talha Bin</ForeName>
            <Initials>TB</Initials>
            <Identifier Source="ORCID">0000-0003-3188-2272</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rabaan</LastName>
            <ForeName>Ali A</ForeName>
            <Initials>AA</Initials>
            <Identifier Source="ORCID">0000-0002-6774-9847</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Medicine, Alfaisal University, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mutair</LastName>
            <ForeName>Abbas Al</ForeName>
            <Initials>AA</Initials>
            <Identifier Source="ORCID">0000-0002-9471-2767</Identifier>
            <AffiliationInfo>
              <Affiliation>Research Center, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Nursing, Wollongong University, Wollongong, NSW, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alawi</LastName>
            <ForeName>Zainab Al</ForeName>
            <Initials>ZA</Initials>
            <Identifier Source="ORCID">0000-0002-7004-7694</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Allergy and Immunology, College of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alhumaid</LastName>
            <ForeName>Saad</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-4552-4513</Identifier>
            <AffiliationInfo>
              <Affiliation>Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dhama</LastName>
            <ForeName>Kuldeep</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-7469-4752</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="Y">T-Lymphocytes, Regulatory</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Autoimmunity</Keyword>
        <Keyword MajorTopicYN="Y">Foxp3</Keyword>
        <Keyword MajorTopicYN="Y">Treg therapy</Keyword>
        <Keyword MajorTopicYN="Y">autoimmune diseases</Keyword>
        <Keyword MajorTopicYN="Y">regulatory T cell (Treg)</Keyword>
        <Keyword MajorTopicYN="Y">self versus non-self</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35240914</ArticleId>
        <ArticleId IdType="pmc">PMC9009914</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2022.2035117</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Arellano B, Graber DJ, Sentman CL.. 
Regulatory T cell-based therapies for autoimmunity. Discov Med. 2016;22:73–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5573148</ArticleId>
            <ArticleId IdType="pubmed">27585233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matzinger P. The danger model: a renewed sense of self. Science (80-). 2002;296:301–05. doi:10.1126/science.1071059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1071059</ArticleId>
            <ArticleId IdType="pubmed">11951032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911. doi:10.1016/j.immuni.2009.03.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2009.03.019</ArticleId>
            <ArticleId IdType="pubmed">19464196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gliwiński M, Iwaszkiewicz-Grześ D, Trzonkowski P. Cell-based therapies with T regulatory cells. BioDrugs. 2017;31:335–47. doi:10.1007/s40259-017-0228-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40259-017-0228-3</ArticleId>
            <ArticleId IdType="pmc">PMC5548816</ArticleId>
            <ArticleId IdType="pubmed">28540499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikami N, Kawakami R, Sakaguchi S. New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression. Curr Opin Immunol. 2020;67:36–41. doi:10.1016/j.coi.2020.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2020.07.004</ArticleId>
            <ArticleId IdType="pubmed">32827951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol. 2010;40:1232–40. doi:10.1002/eji.200940045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.200940045</ArticleId>
            <ArticleId IdType="pubmed">20148422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Zou X, Zhang Y, Wang X, Yang W, Li Y. The generation and regulation of tissue-resident Tregs and their role in autoimmune diseases. J Immunol Res. 2020;2020:1–13. doi:10.1155/2020/8815280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/8815280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocamora-Reverte L, Melzer FL, Würzner R, and Weinberger B. The complex role of regulatory T cells in immunity and aging. Front Immunol
11 . 2021;616949. doi:10.3389/fimmu.2020.616949</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.616949</ArticleId>
            <ArticleId IdType="pmc">PMC7873351</ArticleId>
            <ArticleId IdType="pubmed">33584708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampani E, Stangou M, Daikidou DV, Nikolaidou V, Asouchidou D, Dimitriadis C, Lioulios G, Xochelli A, Fylaktou A, Papagianni A. Influence of end stage renal disease on CD28 expression and T-cell immunity. Nephrology. 2021;26:185–96. doi:10.1111/nep.13784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nep.13784</ArticleId>
            <ArticleId IdType="pubmed">32935413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampani E, Daikidou DV, Lioulios G, Xochelli A, Mitsoglou Z, Nikolaidou V, Dimitriadis C, Fylaktou A, Papagianni A, Stangou M. CD28null and regulatory T cells are substantially disrupted in patients with end-stage renal disease due to diabetes mellitus. Int J Mol Sci. 2021;22:1–13. doi:10.3390/ijms22062975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22062975</ArticleId>
            <ArticleId IdType="pmc">PMC8001943</ArticleId>
            <ArticleId IdType="pubmed">33804135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol. 2009;133:22–26. doi:10.1016/j.clim.2009.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2009.06.001</ArticleId>
            <ArticleId IdType="pubmed">19559653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukhatayev Z, Ostapchuk YO, Fang D, and Le Poole IC. Engineered antigen-specific regulatory T cells for autoimmune skin conditions. Autoimmun Rev
20
3 . 2021;102761. doi:10.1016/j.autrev.2021.102761</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2021.102761</ArticleId>
            <ArticleId IdType="pubmed">33476816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer A, Adoro S, Park JH. Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol. 2008;8:788–801. doi:10.1038/nri2416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2416</ArticleId>
            <ArticleId IdType="pmc">PMC2760737</ArticleId>
            <ArticleId IdType="pubmed">18802443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64. doi:10.1146/annurev.immunol.25.022106.141623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141623</ArticleId>
            <ArticleId IdType="pmc">PMC6066374</ArticleId>
            <ArticleId IdType="pubmed">22224781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nazzal D, Gradolatto A, Truffault F, Bismuth J, and Berrih-Aknin S. Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand. Cell Death Dis
5
9 . 2014;e1420. doi:10.1038/cddis.2014.377</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.377</ArticleId>
            <ArticleId IdType="pmc">PMC4540205</ArticleId>
            <ArticleId IdType="pubmed">25210803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakaguchi S, Sakaguchi N, Asano M, Itoh M, and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155
3 :1151–64. Accessed date 1
August 1995. http://www.ncbi.nlm.nih.gov/pubmed/7636184</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7636184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor β-Dependent STAT5 activation is required for the development of Foxp3 + regulatory T cells. J Immunol. 2007;178:280–90. doi:10.4049/jimmunol.178.1.280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.178.1.280</ArticleId>
            <ArticleId IdType="pubmed">17182565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev. 2014;259:88–102. doi:10.1111/imr.12160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12160</ArticleId>
            <ArticleId IdType="pmc">PMC3982187</ArticleId>
            <ArticleId IdType="pubmed">24712461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:4. doi:10.3389/fimmu.2013.00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2013.00004</ArticleId>
            <ArticleId IdType="pmc">PMC3708155</ArticleId>
            <ArticleId IdType="pubmed">23874336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2006;7:83–92. doi:10.1038/ni1289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1289</ArticleId>
            <ArticleId IdType="pmc">PMC3057888</ArticleId>
            <ArticleId IdType="pubmed">16311599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allos H, Al Dulaijan BS, Choi J, Azzi J. Regulatory T cells for more targeted immunosuppressive therapies. Clin Lab Med. 2019;39:1–13. doi:10.1016/j.cll.2018.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cll.2018.11.001</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253–57. doi:10.1038/nri1032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri1032</ArticleId>
            <ArticleId IdType="pubmed">12658273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lui PPW, Cho I, Ali N. Tissue regulatory T cells. Immunology. 2020;161:4–17. doi:10.1111/imm.13208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imm.13208</ArticleId>
            <ArticleId IdType="pmc">PMC7450170</ArticleId>
            <ArticleId IdType="pubmed">32463116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panduro M, Benoist C, Mathis D. Tissue Tregs. Annu Rev Immunol. 2016;34(1):609–33. doi:10.1146/annurev-immunol-032712-095948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-032712-095948</ArticleId>
            <ArticleId IdType="pmc">PMC4942112</ArticleId>
            <ArticleId IdType="pubmed">27168246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss JM, Bilate AM, Gobert M, Ding Y, de Lafaille MAC, Parkhurst CN, Xiong H, Dolpady J, Frey AB, Ruocco MG, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosagenerated induced Foxp3+ T reg cells. J Exp Med. 2012;209:1723–42. doi:10.1084/jem.20120914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20120914</ArticleId>
            <ArticleId IdType="pmc">PMC3457733</ArticleId>
            <ArticleId IdType="pubmed">22966001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science (80-). 2011;331:337–41. doi:10.1126/science.1198469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1198469</ArticleId>
            <ArticleId IdType="pmc">PMC3969237</ArticleId>
            <ArticleId IdType="pubmed">21205640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scharschmidt TC, Vasquez KS, Truong HA, Gearty SV, Pauli ML, Nosbaum A, Gratz IK, Otto M, Moon JJ, Liese J, et al. A wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes. Immunity. 2015;43:1011–21. doi:10.1016/j.immuni.2015.10.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2015.10.016</ArticleId>
            <ArticleId IdType="pmc">PMC4654993</ArticleId>
            <ArticleId IdType="pubmed">26588783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?
Cancer Sci. 2019;110:2080–89. doi:10.1111/cas.14069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.14069</ArticleId>
            <ArticleId IdType="pmc">PMC6609813</ArticleId>
            <ArticleId IdType="pubmed">31102428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toker A, Engelbert D, Garg G, Polansky JK, Floess S, Miyao T, Baron U, Düber S, Geffers R, Giehr P, et al. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J Immunol. 2013;190:3180–88. doi:10.4049/jimmunol.1203473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1203473</ArticleId>
            <ArticleId IdType="pubmed">23420886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darrasse J, Mardon G, Salomon BL, Catala MKD, Klatzmann D. Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood. 2005;105:4715–21. doi:10.1182/blood-2004-10-4051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2004-10-4051</ArticleId>
            <ArticleId IdType="pubmed">15731180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Barbara BF, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701–11. doi:10.1084/jem.20060772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20060772</ArticleId>
            <ArticleId IdType="pmc">PMC2118339</ArticleId>
            <ArticleId IdType="pubmed">16818678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 1999;59:3128–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10397255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–32. doi:10.1038/nri2343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2343</ArticleId>
            <ArticleId IdType="pmc">PMC2665249</ArticleId>
            <ArticleId IdType="pubmed">18566595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - A diverse arsenal for a moving target. Immunology. 2008;124:13–22. doi:10.1111/j.1365-2567.2008.02813.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2567.2008.02813.x</ArticleId>
            <ArticleId IdType="pmc">PMC2434375</ArticleId>
            <ArticleId IdType="pubmed">18346152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol. 2019;10:10. doi:10.3389/fimmu.2019.00010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00010</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7–13. doi:10.1038/ni.1818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1818</ArticleId>
            <ArticleId IdType="pubmed">20016504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feuerer M, Hill JA, Kretschmer K, Von Boehmer H, Mathis D, Benoist C. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci U S A. 2010;107:5919–24. doi:10.1073/pnas.1002006107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1002006107</ArticleId>
            <ArticleId IdType="pmc">PMC2851866</ArticleId>
            <ArticleId IdType="pubmed">20231436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omenetti S, Pizarro TT, Bancu I, Lauzurica-Valdemoros R, Borràs FE. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Immunol. 2015;6:6. doi:10.3389/fimmu.2015.00006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2015.00006</ArticleId>
            <ArticleId IdType="pmc">PMC4681807</ArticleId>
            <ArticleId IdType="pubmed">26734006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Tran DQ, Lindsey JW, Rhoads JM. The association of gut microbiota and treg dysfunction in autoimmune diseases. Adv Exp Med Biol. 2021;1278:191–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33523449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotot J, Gottschalk C, Leopold S, Knolle PA, Yagita H, Kurts C, Ludwig-Portugall I. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci U S A. 2012;109:10468–73. doi:10.1073/pnas.1201131109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1201131109</ArticleId>
            <ArticleId IdType="pmc">PMC3387068</ArticleId>
            <ArticleId IdType="pubmed">22689978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iikuni N, Lourenço EV, Hahn BH, La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol. 2009;183:1518–22. doi:10.4049/jimmunol.0901163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0901163</ArticleId>
            <ArticleId IdType="pmc">PMC2730469</ArticleId>
            <ArticleId IdType="pubmed">19570829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richards H, Williams A, Jones E, Hindley J, Godkin A, Simon AK, Gallimore A. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology. 2010;131:583–92. doi:10.1111/j.1365-2567.2010.03333.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2567.2010.03333.x</ArticleId>
            <ArticleId IdType="pmc">PMC2999808</ArticleId>
            <ArticleId IdType="pubmed">20722759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewkowicz N, Klink M, Mycko MP, Lewkowicz P. Neutrophil - CD4+CD25+ T regulatory cell interactions: a possible new mechanism of infectious tolerance. Immunobiology. 2013;218:455–64. doi:10.1016/j.imbio.2012.05.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.imbio.2012.05.029</ArticleId>
            <ArticleId IdType="pubmed">22749980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiemessen MM, Jagger AL, Evans HG, Van Herwijnen MJC, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A. 2007;104:19446–51. doi:10.1073/pnas.0706832104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0706832104</ArticleId>
            <ArticleId IdType="pmc">PMC2148309</ArticleId>
            <ArticleId IdType="pubmed">18042719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano M, Fanelli G, Tan N, Nova-Lamperti E, McGregor R, Lechler RI, Lombardi G, Scottà C. Expanded regulatory T cells induce alternatively activated monocytes with a reduced capacity to expand T helper-17 cells. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.01625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kullberg MC, Hay V, Cheever AW, Mamura M, Sher A, Letterio JJ, Shevach EM, Piccirillo CA. TGF-β1 production by CD4+CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol. 2005;35:2886–95. doi:10.1002/eji.200526106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.200526106</ArticleId>
            <ArticleId IdType="pubmed">16180248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18:1332–41. doi:10.1038/ni.3868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3868</ArticleId>
            <ArticleId IdType="pmc">PMC5770150</ArticleId>
            <ArticleId IdType="pubmed">29083399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239–44. doi:10.1038/ni1572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1572</ArticleId>
            <ArticleId IdType="pmc">PMC3075612</ArticleId>
            <ArticleId IdType="pubmed">18285775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006;24:209–26. doi:10.1146/annurev.immunol.24.021605.090547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.24.021605.090547</ArticleId>
            <ArticleId IdType="pubmed">16551248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27:68–73. doi:10.1038/83784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/83784</ArticleId>
            <ArticleId IdType="pubmed">11138001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova J-L-R, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–21. doi:10.1038/83713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/83713</ArticleId>
            <ArticleId IdType="pubmed">11137993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu J, Yamazaki S, Takahashi T, and Ishida YSS. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3
2
135–142. doi:10.1038/ni759</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni759</ArticleId>
            <ArticleId IdType="pubmed">11812990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Regulatory T cells in autoimmune hepatitis. J Hepatol. 2012;57:932–33. doi:10.1016/j.jhep.2012.05.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2012.05.022</ArticleId>
            <ArticleId IdType="pubmed">22748772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aghabi YO, Yasin A, Kennedy JI, Davies SP, Butler AE, and Stamataki Z. Targeting enclysis in liver autoimmunity, transplantation, viral infection and cancer. Front Immunol. 2021;12
662134. doi:10.3389/fimmu.2021.662134</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.662134</ArticleId>
            <ArticleId IdType="pmc">PMC8089374</ArticleId>
            <ArticleId IdType="pubmed">33953725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, DeFor T, Levine BL, June CH, Rubinstein P, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117:1061–70. doi:10.1182/blood-2010-07-293795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2010-07-293795</ArticleId>
            <ArticleId IdType="pmc">PMC3035067</ArticleId>
            <ArticleId IdType="pubmed">20952687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dijke IE, Hoeppli RE, Ellis T, Pearcey J, Huang Q, McMurchy AN, Boer K, Peeters AMA, Aubert G, Larsen I, et al. Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells. Am J Transplant. 2016;16:58–71. doi:10.1111/ajt.13456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajt.13456</ArticleId>
            <ArticleId IdType="pubmed">26414799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Safinia N, Vaikunthanathan T, Fraser H, Thirkell S, Lowe K, Blackmore L, Whitehouse G, Martinez-Llordella M, Jassem W, Sanchez-Fueyo A, et al. Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. Oncotarget. 2016;7:7563–77. doi:10.18632/oncotarget.6927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.6927</ArticleId>
            <ArticleId IdType="pmc">PMC4884938</ArticleId>
            <ArticleId IdType="pubmed">26788992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, Grabowska M, Derkowska I, Juścińska J, Owczuk R, Szadkowska A, Witkowski P, Młynarski W, et al. Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets - Results of one year follow-up. Clin Immunol. 2014;153:23–30. doi:10.1016/j.clim.2014.03.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2014.03.016</ArticleId>
            <ArticleId IdType="pubmed">24704576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fraser H, Safinia N, Grageda N, Thirkell S, Lowe K, Fry LJ, Scottá C, Hope A, Fisher C, Hilton R, et al. A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials. Mol Ther - Methods Clin Dev. 2018;8:198–209. doi:10.1016/j.omtm.2018.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtm.2018.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC5850906</ArticleId>
            <ArticleId IdType="pubmed">29552576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janssens I, and Cools N. Regulating the regulators: is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
Cell Immunol. 2020;358
104236. doi:10.1016/j.cellimm.2020.104236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2020.104236</ArticleId>
            <ArticleId IdType="pubmed">33137651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu D, Wong MQ, Vent-Schmidt J, Boardman DA, Steiner TS, and Levings MK. A method for expansion and retroviral transduction of mouse regulatory T cells. J Immunol Methods. 2021;488
112931. doi:10.1016/j.jim.2020.112931</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jim.2020.112931</ArticleId>
            <ArticleId IdType="pubmed">33221458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Boyman O, Caramori G, Cari L, Fan Chung K, Diamant Z, et al. Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy Eur J Allergy Clin Immunol. 2021;76:90–113. doi:10.1111/all.14478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.14478</ArticleId>
            <ArticleId IdType="pubmed">32593226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eggenhuizen PJ, Ng BH, Ooi JD. Treg enhancing therapies to treat autoimmune diseases. Int J Mol Sci. 2020;21:1–18. doi:10.3390/ijms21197015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21197015</ArticleId>
            <ArticleId IdType="pmc">PMC7582931</ArticleId>
            <ArticleId IdType="pubmed">32977677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology. 2012:143. doi:10.1186/1471-230X-12-143</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-230X-12-143</ArticleId>
            <ArticleId IdType="pubmed">22885333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg R, Scotta C, Cooper D, Nissim-Eliraz E, Nir E, Tasker S, Irving PM, Sanderson J, Lavender P, Ibrahim F, et al. Correction of defective T-Regulatory cells from patients with crohn’s disease by ex vivo ligation of retinoic acid receptor-α. Gastroenterology. 2019;156:1775–87. doi:10.1053/j.gastro.2019.01.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2019.01.025</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K. Type 1 diabetes immunotherapy using polyclonal Tregs. Sci Transl Med. 2015. 
Nov
25;7:315ra189. doi:10.1126/scitranslmed.aad4134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aad4134</ArticleId>
            <ArticleId IdType="pmc">PMC4729454</ArticleId>
            <ArticleId IdType="pubmed">26606968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dall’Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, et al. Adoptive Treg cell therapy in a patient with systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:431–40. doi:10.1002/art.40737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.40737</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terry LV, Oo YH. The next frontier of regulatory T cells: promising immunotherapy for autoimmune diseases and organ transplantations. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00011</ArticleId>
            <ArticleId IdType="pmc">PMC7538686</ArticleId>
            <ArticleId IdType="pubmed">33072105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42. doi:10.1038/39614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/39614</ArticleId>
            <ArticleId IdType="pubmed">9338786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4 + CD25 + Regulatory T Cells. J Immunol. 2003;170:3939–43. doi:10.4049/jimmunol.170.8.3939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.170.8.3939</ArticleId>
            <ArticleId IdType="pubmed">12682220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goswami TK, Joardar SN, Ram GC, Banerjee R, Singh DK. Association of mycobacterium paratuberculosis in Crohn’s disease and Johne’s disease: a possible zoonotic threat. Curr Sci. 2000;79:1076–81.</Citation>
        </Reference>
        <Reference>
          <Citation>Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868–78. doi:10.1053/j.gastro.2005.03.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2005.03.043</ArticleId>
            <ArticleId IdType="pubmed">15940622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer J-P, Groux H. A comparative study between T regulatory Type 1 and CD4 + CD25 + T cells in the control of inflammation. J Immunol. 2003;171:5018–26. doi:10.4049/jimmunol.171.10.5018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.171.10.5018</ArticleId>
            <ArticleId IdType="pubmed">14607898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canavan JB, Scottà C, Vossenkämper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn’s disease. Gut. 2016;65:584–94. doi:10.1136/gutjnl-2014-306919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2014-306919</ArticleId>
            <ArticleId IdType="pmc">PMC4819603</ArticleId>
            <ArticleId IdType="pubmed">25715355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8 + regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol. 2005;174:5814–22. doi:10.4049/jimmunol.174.9.5814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.174.9.5814</ArticleId>
            <ArticleId IdType="pubmed">15843585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, Xu L, Priatel JJ, Levings MK, Tan R. Cutting edge: increased IL-17–secreting T cells in children with new-onset type 1 diabetes. J Immunol. 2010;185:3814–18. doi:10.4049/jimmunol.1001860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1001860</ArticleId>
            <ArticleId IdType="pubmed">20810982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baeten P, Van Zeebroeck L, Kleinewietfeld M, Hellings N, Broux B. Improving the efficacy of regulatory T cell therapy. Clin Rev Allergy Immunol. 2021. doi:10.1007/s12016-021-08866-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-021-08866-1</ArticleId>
            <ArticleId IdType="pmc">PMC8256646</ArticleId>
            <ArticleId IdType="pubmed">34224053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugiyama H, Matsue H, Nagasaka A, Nakamura Y, Tsukamoto K, Shibagaki N, Kawamura T, Kitamura R, Ando N, Shimada S. CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. Dermatology. 2007;214:210–20. doi:10.1159/000099585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000099585</ArticleId>
            <ArticleId IdType="pubmed">17377382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoyama T, Matsuda S, Takae Y, Wada N, Nishikawa T, Amagai M, Koyasu S. Antigen-independent development of Foxp31 regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris. Int Immunol. 2011;23:365–73. doi:10.1093/intimm/dxr020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxr020</ArticleId>
            <ArticleId IdType="pubmed">21525154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt T, Willenborg S, Hünig T, Deeg CA, Sonderstrup G, Hertl M, Eming R. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris. Exp Dermatol. 2016;25:293–98. doi:10.1111/exd.12919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/exd.12919</ArticleId>
            <ArticleId IdType="pubmed">26661498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6509547</ArticleId>
            <ArticleId IdType="pubmed">31130959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buitrago-Molina LE, Pietrek J, Noyan F, Schlue J, Manns MP, Wedemeyer H, Hardtke-Wolenski M, and Jaeckel E. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun. 2021;117
102591. doi:10.1016/j.jaut.2020.102591</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2020.102591</ArticleId>
            <ArticleId IdType="pubmed">33387980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longhi MS, Mieli-Vergani G, and Vergani D. Regulatory T cells in autoimmune hepatitis: un updated overview. J Autoimmun. 2021;119
102619. doi:10.1016/j.jaut.2021.102619</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2021.102619</ArticleId>
            <ArticleId IdType="pmc">PMC8044040</ArticleId>
            <ArticleId IdType="pubmed">33652348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sebode M, Hartl J, Vergani D, Lohse AW. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int. 2018;38:15–22. doi:10.1111/liv.13458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/liv.13458</ArticleId>
            <ArticleId IdType="pubmed">28432836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31–37. doi:10.1016/j.jhep.2004.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2004.03.008</ArticleId>
            <ArticleId IdType="pubmed">15246204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse AW, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012;57:125–32. doi:10.1016/j.jhep.2012.02.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2012.02.029</ArticleId>
            <ArticleId IdType="pubmed">22425700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeffery HC, Jeffery LE, Lutz P, Corrigan M, Webb GJ, Hirschfield GM, Adams DH, Oo YH. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394–411. doi:10.1111/cei.12940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12940</ArticleId>
            <ArticleId IdType="pmc">PMC5422719</ArticleId>
            <ArticleId IdType="pubmed">28176332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim TY, Martinez-Llordella M, Kodela E, Gray E, Heneghan MA, Sanchez-Fueyo A. Low-dose interleukin-2 for refractory autoimmune hepatitis. Hepatology. 2018;68:1649–52. doi:10.1002/hep.30059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.30059</ArticleId>
            <ArticleId IdType="pubmed">29698571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taubert R, Hardtke-Wolenski M, Noyan F, Wilms A, Baumann AK, Schlue J, Olek S, Falk CS, Manns MP, Jaeckel E. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61:1106–14. doi:10.1016/j.jhep.2014.05.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2014.05.034</ArticleId>
            <ArticleId IdType="pubmed">24882050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier. J Allergy Clin Immunol. 2018;142:1710–18. doi:10.1016/j.jaci.2018.10.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2018.10.015</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–30. doi:10.1038/nrrheum.2016.186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId>
            <ArticleId IdType="pubmed">27872476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humrich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, Weigert O, Kloke L, Heimann J, Gaber T, Brandenburg S, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A. 2010;107:204–09. doi:10.1073/pnas.0903158107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0903158107</ArticleId>
            <ArticleId IdType="pmc">PMC2806746</ArticleId>
            <ArticleId IdType="pubmed">20018660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344–55. doi:10.1002/eji.201344280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201344280</ArticleId>
            <ArticleId IdType="pubmed">25378177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt A, Rieger CC, Venigalla RK, Éliás S, Max R, Lorenz HM, Gröne HJ, Krammer PH, Kuhn A. Analysis of FOXP3+ regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus. Immunol Res. 2017;65:551–63. doi:10.1007/s12026-017-8904-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12026-017-8904-4</ArticleId>
            <ArticleId IdType="pubmed">28224362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR, Yoo WH. Altered frequency and migration capacity of CD4+ CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology. 2008;47:789–94. doi:10.1093/rheumatology/ken108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/ken108</ArticleId>
            <ArticleId IdType="pubmed">18388146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22:991–93. doi:10.1038/nm.4148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4148</ArticleId>
            <ArticleId IdType="pubmed">27500725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizui M, Tsokos GC. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front Immunol. 2018;9:786. doi:10.3389/fimmu.2018.00786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00786</ArticleId>
            <ArticleId IdType="pmc">PMC5932391</ArticleId>
            <ArticleId IdType="pubmed">29755456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38. doi:10.1016/S0140-6736(16)30173-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)30173-8</ArticleId>
            <ArticleId IdType="pubmed">27156434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmström V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6:6. doi:10.1186/ar1025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar1025</ArticleId>
            <ArticleId IdType="pmc">PMC464877</ArticleId>
            <ArticleId IdType="pubmed">15225369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han GM, O’Neil-Andersen NJ, Zurier RB, Lawrence DA. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008;253(1–2):92–101. doi:10.1016/j.cellimm.2008.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2008.05.007</ArticleId>
            <ArticleId IdType="pmc">PMC2585376</ArticleId>
            <ArticleId IdType="pubmed">18649874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu MF, Wang CR, Fung LL, Lin LH, Tsai CN. The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. Scand J Immunol. 2005;62:312–17. doi:10.1111/j.1365-3083.2005.01656.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-3083.2005.01656.x</ArticleId>
            <ArticleId IdType="pubmed">16179019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawson CA, Brown AK, Bejarano V, Douglas SH, Burgoyne CH, Greenstein AS, Boylston AW, Emery P, Ponchel F, Isaacs JD. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology. 2006;45:1210–17. doi:10.1093/rheumatology/kel089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kel089</ArticleId>
            <ArticleId IdType="pubmed">16571607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2008;105:19396–401. doi:10.1073/pnas.0806855105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0806855105</ArticleId>
            <ArticleId IdType="pmc">PMC2614772</ArticleId>
            <ArticleId IdType="pubmed">19036923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med. 2007;204:33–39. doi:10.1084/jem.20061531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20061531</ArticleId>
            <ArticleId IdType="pmc">PMC2118431</ArticleId>
            <ArticleId IdType="pubmed">17200409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3 + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev. 2011;10:744–55. doi:10.1016/j.autrev.2011.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2011.05.004</ArticleId>
            <ArticleId IdType="pubmed">21621000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morita T, Shima Y, Wing JB, Sakaguchi S, Ogata A, and Kumanogoh A. The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-Analysis. PLoS One. 2016;11
9
e0162306 doi:10.1371/journal.pone.0162306. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0162306</ArticleId>
            <ArticleId IdType="pmc">PMC5021283</ArticleId>
            <ArticleId IdType="pubmed">27622457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelchtermans H, De Klerck B, Mitera T, Van Balen M, Bullens D, Billiau A, Leclercq G, Matthys P. Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther. 2005;7:402–15. doi:10.1186/ar1500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar1500</ArticleId>
            <ArticleId IdType="pmc">PMC1065335</ArticleId>
            <ArticleId IdType="pubmed">15743488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan ME, Flierman R, Van Duivenvoorde LM, Witteveen HJ, Van Ewijk W, Van Laar JM, De Vries RRP, Toes REM. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 2005;52:2212–21. doi:10.1002/art.21195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.21195</ArticleId>
            <ArticleId IdType="pubmed">15986351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaiss MM, Axmann R, Zwerina J, Polzer K, Gückel E, Skapenko A, Schulze-Koops H, Horwood N, Cope A, Schett G. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007;56:4104–12. doi:10.1002/art.23138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.23138</ArticleId>
            <ArticleId IdType="pubmed">18050211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum. 2007;56:732–42. doi:10.1002/art.22414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.22414</ArticleId>
            <ArticleId IdType="pubmed">17328044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeRoy EC, Medsger TJ. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11469464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frantz C, Auffray C, Avouac J, Allanore Y. Regulatory T cells in systemic sclerosis. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.02356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, Osella-Abate S, De Simone C, Marzano A, Bernengo MG, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162:1056–63. doi:10.1111/j.1365-2133.2010.09633.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2133.2010.09633.x</ArticleId>
            <ArticleId IdType="pubmed">20105169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kataoka H, Yasuda S, Fukaya S, Oku K, Horita T, Atsumi T, Koike T. Decreased expression of Runx1 and lowered proportion of Foxp3+ CD25+ CD4+ regulatory T cells in systemic sclerosis. Mod Rheumatol. 2015;25:90–95. doi:10.3109/14397595.2014.899736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/14397595.2014.899736</ArticleId>
            <ArticleId IdType="pubmed">24716598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein S, Kretz CC, Ruland V, Stumpf C, Haust M, Hartschuh W, Hartmann M, Enk A, Suri-Payer E, Oberle N, et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis. 2011;70:1475–81. doi:10.1136/ard.2009.116525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2009.116525</ArticleId>
            <ArticleId IdType="pubmed">21097800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsukamoto H, Nagafuji K, Horiuchi T, Mitoma H, Niiro H, Arinobu Y, Inoue Y, To K, Miyamoto T, Iwasaki H, et al. Analysis of immune reconstitution after autologous CD34 + stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4 + t cells. Rheumatology. 2011;50:944–52. doi:10.1093/rheumatology/keq414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keq414</ArticleId>
            <ArticleId IdType="pubmed">21172925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vonk MC, Marjanovic Z, Van Den Hoogen FHJ, Zohar S, Schattenberg AVMB, Fibbe WE, Larghero J, Gluckman E, Van Laar JM, Farge D, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008;67:98–104. doi:10.1136/ard.2007.071464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2007.071464</ArticleId>
            <ArticleId IdType="pubmed">17526554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verstappen GM, Kroese FGM, Bootsma H. T cells in primary Sjögren’s syndrome: targets for early intervention. Rheumatol (United Kingdom). 2021;60:3088–98.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu MF, Lin LH, Weng CT, Weng M. Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sjogren’s syndrome. Lupus. 2008;17:34–39. doi:10.1177/0961203307085248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203307085248</ArticleId>
            <ArticleId IdType="pubmed">18089681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM. Foxp3+ T-regulatory cells in Sjögren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol. 2008;173:1389–96. doi:10.2353/ajpath.2008.080246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2008.080246</ArticleId>
            <ArticleId IdType="pmc">PMC2570129</ArticleId>
            <ArticleId IdType="pubmed">18818377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021;184:14–24. doi:10.1111/bjd.19380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.19380</ArticleId>
            <ArticleId IdType="pubmed">32628773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong F, Li XH, Zhang KM, Yin GH. Functional characterization of CD4+ CD25+ regulatory T cells differentiated in vitro from bone marrow-derived hematopoietic cells of psoriatic patients. J Clin Dermatology. 2008;37:207–09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18070209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW. Increased Th17 cells are accompanied by FoxP3+ Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol. 2010;135:108–17. doi:10.1016/j.clim.2009.11.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2009.11.008</ArticleId>
            <ArticleId IdType="pubmed">20006553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, Cooper KD. Dysfunctional blood and target tissue CD4 + CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174:164–73. doi:10.4049/jimmunol.174.1.164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.174.1.164</ArticleId>
            <ArticleId IdType="pmc">PMC2903964</ArticleId>
            <ArticleId IdType="pubmed">15611238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yun WJ, Lee DW, Chang SE, Yoon GS, Huh JR, Won CH, Lee MW, Kim SE, Kim BJ, Moon KC, et al. Role of CD4+CD25high+FOXP3+ regulatory T cells in psoriasis. Ann Dermatol. 2010;22:397–403. doi:10.5021/ad.2010.22.4.397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5021/ad.2010.22.4.397</ArticleId>
            <ArticleId IdType="pmc">PMC2991715</ArticleId>
            <ArticleId IdType="pubmed">21165208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Z, Li W, Su W. Tregs in autoimmune uveitis. Adv Exp Med Biol. 2021;1278:205–27. doi:10.1007/978-981-15-6407-9_11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-981-15-6407-9_11</ArticleId>
            <ArticleId IdType="pubmed">33523450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Luo J, Garden OA, Christensen CB, Lildal T, Pedersen M, Magnusson M, Borghammer P, Ovesen T. Immunoregulatory cells in myasthenia gravis. Front Neurol. 2020;11:11. doi:10.3389/fneur.2020.00011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00011</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrnstadt GR, Steinmetz OM. The role of Treg subtypes in glomerulonephritis. Cell Tissue Res. 2020;385(2):293–304. doi:10.1007/s00441-020-03359-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-020-03359-7</ArticleId>
            <ArticleId IdType="pmc">PMC8523467</ArticleId>
            <ArticleId IdType="pubmed">33315130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann K, Tiegs G. Immune regulation in renal inflammation. Cell Tissue Res. 2021;385(2):305–22. doi:10.1007/s00441-020-03351-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00441-020-03351-1</ArticleId>
            <ArticleId IdType="pmc">PMC8523435</ArticleId>
            <ArticleId IdType="pubmed">33496881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riley JL, June CH, Blazar BR. Human T regulatory cells as therapeutic agents: take a billion or so of these and call me in the morning. Immunity. 2010;30:656–65. doi:10.1016/j.immuni.2009.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2009.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC2742482</ArticleId>
            <ArticleId IdType="pubmed">19464988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Millis JM, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16:371–75. doi:10.1016/j.intimp.2013.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2013.02.001</ArticleId>
            <ArticleId IdType="pubmed">23428908</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
